K-232 phase 3 comparative study compared to ripasudil ophthalmic solutio
Phase 3
Completed
- Conditions
- primary open-angle glaucoma (broad definition), ocular hypertension
- Registration Number
- JPRN-jRCT2080225065
- Lead Sponsor
- Kowa Company, Ltd.
- Brief Summary
The superiority of the IOP-lowering effect of K-232 to ripasudil was confirmed. Regarding the safety of K-232, there were no clinically significant adverse events or adverse drug reactions.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- completed
- Sex
- All
- Target Recruitment
- 228
Inclusion Criteria
1. POAG (broad definition) or OH patients
2. IOP after ripasudil run-in period => 18mmHg
Exclusion Criteria
1.Patients whose visual acuity is below 0.3
2.Patients thought to use glaucoma medication during this trial
3.Patients thought to wear contact lenses during this trial
etc.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method